Biogen Idec (BIIB): O‘sish sur’atiga tuzatilgan narx-foyda
Biogen Inc. qiyin patologiyalarni davolovchi eksklyuziv dori vositalari uchun premium narxlarni qat'iy ekologik mas'uliyat bilan birlashtiradi. GURU.Markets terminal grafigidagi balanslashtirilgan narx-foyda va o'sish koeffitsiyenti joriy dinamikani aks ettiradi, bunda 2.48 bugungi metrika qiymatini ifodalaydi. Biznes hozirda siklik pasayishni yengib chiqish uchun yangi dori vositalarining tijorat muvaffaqiyatini kutgan holda, portfelni yangilash jarayonidan o'tmoqda.
Biogen Inc. (BIIB) - koʻrsatkichlar kesimi va moliyaviy hisobotlar
- narx va narxlar bo'yicha konsensus prognoz:
- birja kapitallashuvi ma'lumotlari:
- aksiyadorlik kapitalining balans qiymati ma'lumotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning xususiy kapitalga nisbati Biogen Inc.|BIIB - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati biogen.com|BIIB - Kompaniyaning jamlangan qarzlari|Sof aktivlarga qarzlar Biogen Corp|BIIB - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi Biogen|Tezkor likvidlik ko‘rsatkichi biogen.com
- foyda va bozor multiplikatorlari tafsilotlari:
BIIB - Sof daromad|Kompaniya foydasi prognozi Biogen Inc.|BIIB - P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Biogen Idec|BIIB - PEG multiplikatori|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Biogen Corp|BIIB - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Biogen|BIIB - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sishi biogen.com|BIIB - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foydaning prognoz qilingan o'sish sur'ati Biogen Inc.
Kompaniyaning umumiy tahlili:BIIB, Biogen Inc
Yangi Altsgeymer kasalligi davolash vositalarini targ'ib qilishning yuqori xarajatlari va eski mahsulotlarning stagnatsiyasi Biogen Inc. (BIIB) kompaniyasining joriy marjalarini cheklamoqda. O'sishga nisbatan ushbu past baholanganlik ko'rsatkichi P/E koeffitsientini foyda o'sish sur'atlari bilan solishtirib, biznes kengayish dinamikasi aksiyalarining joriy bozor qiymatini oqlash-oklamasligini yoki aktiv o'z potentsialiga nisbatan chegirma bilan savdo qilinayotganini aniqlaydi.
Biogen Inc. raqobatchilari
O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Neurocrine|Narxning foydaga va o‘sish sur’atiga nisbati Regencell RGC|Axsome Corp (AXSM) - O‘sish sur’atiga tuzatilgan narx-foyda|ACADIA Pharmaceuticals - PEG multiplikatori|Narxning sof foyda o‘sishiga nisbati xenon-pharma.com (XENE)|VKTX: PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Supernus Pharmaceuticals, Inc. (SUPN)|Narxning foydaga va o‘sish sur’atiga nisbati Catalyst Pharmaceuticals Inc|O‘sishni hisobga olgan narx-foyda koeffitsiyenti DNLI (Denali Corp)|Narx-foyda va o‘sish multiplikatori HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori AMLX (Amylyx Pharmaceuticals, Inc.)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Trevi Therapeutics Inc (TRVI)|PRAX - Narxning foydaga va o‘sish sur’atiga nisbati|AVXL (Anavex Life Sciences Corp) - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|CBLL: PEG multiplikatori|Narx-foyda va o‘sish multiplikatori Prothena|Narx-foyda va o‘sish multiplikatori ALEC|Annexon Biosciences (ANNX) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|PEG multiplikatori OMER|Narxning foydaga va o‘sish sur’atiga nisbati NGNE (Neurogene Therapeutics)|PEG multiplikatori ACIU (AC Immune)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati voyagertherapeutics.com (VYGR)|Neumora Therapeutics, Inc. - PEG multiplikatori|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Scilex Holding SCLX|TVGN: PEG multiplikatori|ACOG (Alpha Cognition Inc.) - Narxning foydaga va o‘sish sur’atiga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Cognition Therapeutics|O‘sishni hisobga olgan narx-foyda koeffitsiyenti IKT (inhibikase.com)|PEG multiplikatori SAVA|ASRT - O‘sish sur’atiga tuzatilgan narx-foyda|Coya Therapeutics - Narx-foyda va o‘sish multiplikatori|PEG multiplikatori VistaGen Therapeutics, Inc. VTGN|OVID - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti ABOS (acumenpharm.com)|CervoMed (CRVO) - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atiga tuzatilgan narx-foyda Alterity Therapeutics Limited (ATHE)|CLNN (Clene Inc) - PEG multiplikatori|Narxning foydaga va o‘sish sur’atiga nisbati PEPG|PEG multiplikatori JUNS|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati relmada.com|Narxning foydaga va o‘sish sur’atiga nisbati Annovis Bio ANVS|Grace Therapeutics Inc (GRCE) - O‘sish sur’atiga tuzatilgan narx-foyda|Firefly Neuroscience Inc - PEG multiplikatori|Narxning sof foyda o‘sishiga nisbati Klotho Neurosciences Inc (KLTO)|NRSN: PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda revivapharma.com (RVPH)|Narxning foydaga va o‘sish sur’atiga nisbati MetaVia Inc.|O‘sishni hisobga olgan narx-foyda koeffitsiyenti NRXS (NeurAxis Inc.)|Narx-foyda va o‘sish multiplikatori HSDT (Helius Medical)|PASG (passagebio.com) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori NEUP (Neuphoria Therapeutics)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati minervaneurosciences.com (NERV)|ATHA - Narxning foydaga va o‘sish sur’atiga nisbati|ADXN (Addex Therapeutics Ltd.) - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|ALZN: PEG multiplikatori|Narx-foyda va o‘sish multiplikatori Cyclerion Therapeutics, Inc.|Narx-foyda va o‘sish multiplikatori PTIX|Pasithea (KTTA) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|PEG multiplikatori CRGT|Narxning foydaga va o‘sish sur’atiga nisbati ATXI (Avenue Therapeutics Inc.)|PEG multiplikatori BCLI (Brainstorm Cell Therapeutics, Inc.)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Cara Therapeutics Inc (CARA)|Chromocell Therapeutics - PEG multiplikatori|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Eliem Therapeutics ELYM|ITCI: PEG multiplikatori|LBPH (Longboard Pharmaceuticals Inc) - Narxning foydaga va o‘sish sur’atiga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati Marinus|O‘sishni hisobga olgan narx-foyda koeffitsiyenti NKGN (NKGen Biotech Corp)|PEG multiplikatori NRBO|SAGE - O‘sish sur’atiga tuzatilgan narx-foyda|Synaptogenix - Narx-foyda va o‘sish multiplikatori|PEG multiplikatori Trevena Inc. TRVN|VIGL - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti WENA (Anew Medical Inc.)|Cerevel Therapeutics (CERE) - Narxning foydaga va o‘sish sur’atiga nisbati
